Rongbo Wen

Rongbo Wen

Auto-generated profile, based on publicly available information

Rongbo Wen

Colorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
RWRongbo Wen
Rongbo Wen
LZLeqi Zhou
Leqi Zhou
SJSiyuan Jiang
Siyuan Jiang
HFHao Fan
Hao Fan
KZKuo Zheng
Kuo Zheng
WZWei Zhang
Wei Zhang

7 August 2026 in Oncogene
Verified
Journal Article
Closed access
PDF file
QWQinqin Wang
Qinqin Wang
GYGuanyu Yu
Guanyu Yu
LFLi Feng
Li Feng
ZLZimeng Li
Zimeng Li
RWRongbo Wen
Rongbo Wen
CLChen Li
Chen Li

29 July 2026 in iMetaMed
Verified
Journal Article
Open access
JWJiayue Wu
Jiayue Wu
RWRongbo Wen
Rongbo Wen
TZTianshuai Zhang
Tianshuai Zhang
FCFuao Cao
Fuao Cao
XZXiaoming Zhu
Xiaoming Zhu
GYGuanyu Yu
Guanyu Yu
Immune checkpoint inhibitors (ICIs) have been utilized extensively and shown to be therapeutically beneficial in the treatment of solid tumors in recent years. Nonetheless, considerable heterogeneity in Colorectal cancer (CRC) requires careful consideration. ICIs monotherapy demonstrated notable therapeutic effects in microsatellite unstable mismatch repair‐deficient (MSI‐H/dMMR) CRC with high immunogenicity and tumor mutation load (TMB); however, the response rate of ICIs monotherapy was low in microsatellite stable mismatch repair‐normal (MSS/pMMR) CRC with low TMB and immunosuppressive microenvironment. This article introduces the application status of ICIs monotherapy in CRC, and proposes that combined immunotherapy may be the key to solving its drug resistance. Then it summarizes the exploration and progress of CRC immunotherapy combined with radiotherapy, chemotherapy, targeted therapy, intestinal flora, oncolytic virus, tumor vaccine, and other treatments in recent years, and looks forward to the future research direction and application prospect of combined immunotherapy.